Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Chim, Chor Sang ^a   Lie, Albert Kwok Wai ^a   Chan, Eric Yuk Tat ^a   Liu, Herman Sung Yu ^b   Lau, Ching Wa ^c   Yip, Sze Fai ^c   Sim, Joycelyn ^d   Wan, Thomas Shek Kong ^a   Ma, Edmond Shiu Kwan ^e   Liang, Raymond ^a   Tse, Eric ^a   Kwong, Yok Lam ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^c TUEN MUN HOSPITAL   (Hong Kong)

^d PRINCESS MARGARET HOSPITAL   (Hong Kong)

^e HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

Deep vein thrombosis; Myeloma; PAD; Prognostic factors; Staged approach; VTD

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CHINESE; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELOMA; OVERALL SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERNATIONAL AGENCIES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PYRAZINES; REMISSION INDUCTION; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME; VINCRISTINE;

EID: 84861922411     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-28     Document Type: Article

References (16)

1. A phase 2 study of bortezomib in relapsed, refractory myeloma. PG Richardson, B Barlogie, J Berenson, et al. N Engl J Med 2003 348 2609 2617 10.1056/NEJMoa030288 12826635 (Pubitemid 36741588)
2. Restoration of chemosensitivity by Bortezomib: implications for refractory myeloma. CS Chim, YY Hwang, C Pang, TW Shek, Nat Rev Clin Oncol 2009 6 237 240 10.1038/nrclinonc.2009.15 19333230
3. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. M Cavo, SV Rajkumar, A Palumbo, et al. Blood 2011 117 6063 6073 10.1182/blood-2011-02-297325 21447828
4. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. R Popat, HE Oakervee, S Hallam, et al. Br J Haematol 2008 141 512 516 10.1111/j.1365-2141. 2008.06997.x 18371113 (Pubitemid 351550543)
5. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. JF San Miguel, R Schlag, NK Khuageva, et al. N Engl J Med 2008 359 906 917 10.1056/NEJMoa0801479 18753647
6. A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. CS Chim, AK Lie, EY Chan, et al. Ann Hematol 2010 89 1019 1027 10.1007/s00277-010-0959-4 20428873
7. Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and Urine. AR Bradwell, HD Carr-Smith, GP Mead, et al. Clin Chem 2001 47 673 680 11274017 (Pubitemid 32275810)
8. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and Group for Blood and Marrow Transplant. J Bladé D Samson, D Reece, et al. Br J Haematol 1998 102 1115 1123 10.1046/j.1365-2141.1998.00930.x 9753033 (Pubitemid 28435189)
9. International staging system for multiple myeloma. PR Greipp, J San Miguel, BG Durie, et al. J Clin Oncol 2005 23 3412 3420 10.1200/JCO.2005.04.242 15809451
10. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. CB Reeder, DE Reece, V Kukreti, et al. Leukemia 2009 23 1337 1341 10.1038/leu.2009.26 19225538
11. GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. M Cavo, P Tacchetti, F Patriarca, et al. Lancet 2010 376 2075 2085 10.1016/S0140-6736(10)61424-9 21146205
12. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. P Moreau, H Avet-Loiseau, T Facon, et al. Blood 2011 118 5752 5758 10.1182/blood-2011-05-355081 21849487
13. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. CS Mitsiades, FE Davies, JP Laubach, et al. J Clin Oncol 2011 29 1916 1923 10.1200/JCO.2010.34.0760 21482978
14. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). H Avet-Loiseau, X Leleu, M Roussel, et al. J Clin Oncol 2010 28 4630 4634 10.1200/JCO.2010.28.3945 20644101
15. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. HJ van de Velde, X Liu, G Chen, A Cakana, W Deraedt, M Bayssas, Haematologica 2007 92 1399 1406 10.3324/haematol.11534 18024376 (Pubitemid 350144158)
16. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. JJ Lahuerta, MV Mateos, J Martínez-Lápez, et al. J Clin Oncol 2008 26 5775 5782 10.1200/JCO.2008.17.9721 19001321